Walgreens’ core business is struggling as public and private healthcare payors push for lower healthcare spending, Seeking Alpha reports.
Since its troubles began to surface four years ago, Walgreens has gradually lost its long-term backers, mirrored in the 52% decline in share price.
The company is spending aggressively on primary care at the expense of the health of its balance sheet.
The opioid settlement was a severe setback for Walgreens and its shareholders in FQ1, costing the company $5.9 billion and leading to an operating loss of $6.2 billion. Read more.
